Stockreport

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Ocugen, Inc.  (OCGN) 
PDF Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializ [Read more]